|
|
|
|
|
|
|
|
|
|
the financing round of PerioTrap has just started. This is co-financing with bmp Ventures, one of the leading venture capital companies for high-tech startups. bmp Ventures invests 1 million EUR.
We are pleased to present the second Companisto financing round of a biotech deal: PerioTrap Pharmaceuticals GmbH, an innovative spin-off of the renowned Fraunhofer Institute. PerioTrap is developing a revolutionary treatment for periodontitis, a serious gum disease that affects over a billion people worldwide. |
|
|
|
|
|
|
The challenge: Effective periodontitis treatment
Periodontitis, a serious gum disease, can lead to loose teeth and even complete tooth loss. The current prevention through mouthwashes containing harmful chlorhexidine often also destroys the beneficial bacteria in the mouth. It is one of the last major unresolved dental problems.
PerioTrap has now made the breakthrough: The specially developed active ingredient acts selectively against the disease-causing bacterium, without damaging the healthy microbiome – a completely new approach in dental biotechnology.
After the successful market entry with dental gel and microbiome toothpaste, PerioTrap is now entering the next growth phase: Follow-up financing with bmp Ventures as a co-investor ensures the scaling of sales with Road to Exit by 2028.
|
|
|
|
|
|
|
|
| INVESTMENT HIGHLIGHTS |
|
|
|
|
| • |
|
Co-financing with bmp Ventures (1 million €). |
|
|
| • |
|
Successful market entry: Microbiome toothpaste (Consumer) and dental gel (Professional) sold through pharmacies and dentists. |
|
|
| • |
|
Strong group of shareholders: Fraunhofer Venture, bmp Ventures, EMS Dental (world market leader in the field of dental prophylaxis). |
|
|
| • |
|
Large growth market: Periodontosis - 1 billion people affected worldwide. |
|
|
| • |
|
Spin-Off of the Fraunhofer Institute: Long-term product development, research and patents. |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
| In the pitch video, you will learn more about the areas of application of the new active ingredient as a daily product (toothpaste + mouthwash) as well as in professional dental treatment. |
|
| WATCH NOW → |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Companisto GmbH |
|
Köpenicker Str. 154, 10997 Berlin
Managing Director: Tamo Zwinge, LL. M. and David Rhotert
Amtsgericht: Berlin Charlottenburg HRB 132811 B
VAT-ID: DE 276 014 929
Phone: +49 30 330 837 49
Email: service@companisto.com |
|
|
|
|
|
|
|
|
| You receive this newsletter because you have subscribed to it. You can unsubscribe at any time via the unsubscribe link. |
|
| The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity. |
|
|
|
|
